Our history traces back to one of the world’s most successful healthcare entrepreneurial stories.

The Bueno family founded Amil in the 1970’s and built it to be Latin America’s largest healthcare company. In 2012, UnitedHealth Group, the world's largest healthcare company, acquired a controlling stake in Amil in what came to be the largest ever U.S. company-directed investment in Brazil.

The Buenos were DNA Capital’s first investors.

Building leading healthcare companies

DNA Capital was founded with the goal of building leading healthcare companies. Our goal is to connect, accelerate and optimize companies.

Today we are a global healthcare investment firm.

Operating from Brazil and the USA

We partner with early to late-stage companies, across a variety of geographies, to build leaders in healthcare.

Ranging from early-stage venture capital investments to late-stage private equity transactions, we have a team of seasoned professionals investing globally.

Our history

  • 1978

    Edson Bueno and Dulce founded Amil, a health insurance startup in the state of Rio de Janeiro, Brazil.

  • 2007

    After decades of innovation and growth, Amil goes public on the Brazilian stock market, consolidating its position as the #1 healthcare company in Brazil.

  • 2012

    UnitedHealth Group (UHG) acquires a controlling stake in Amil. The transaction was the largest acquisition of a Brazilian company to date. Edson Bueno joins UHG's board of directors.

  • 2013

    DNA is founded by Pedro Bueno and raises its first private equity fund supported by the Bueno family.

  • 2014

    DNA invests in DASA (5th largest diagnostics company in the world) and Lavebrás.

  • 2016

    DNA invests in Mafra, Latin America's leading integrated healthcare services and products provider for hospitals.

  • 2017

    DNA makes its first investment in a healthcare technology startup, in what would later become its venture capital practice.

  • 2018

    Mafra acquires Cremer, Brazil's leading manufacturer of healthcare disposable supplies.

  • 2019

    DNA launches a San Francisco office to broaden its reach into the US healthcare technology market.

  • 2020

    DNA acquires a controling stake at Mafra, increasing the company's leading position in the Brazilian market.